introduction patients with hepatitis c are commonly treated with combination of pegylated interferon alfa-2a and ribavirin. less than 1% of patients receiving this treatment experience very uncommon ophthalmological side effects such as optic neuropathy and vision disorder, which are usually subclinical, mild and reversible, not requiring the withdrawal of the treatment. retinopathy is the most...

background treatment with peginterferon alpha-2b plus ribavirin is the current standard therapy for chronic hepatitis c (chc). however, many host related and viral parameters are associated with different outcomes of combination therapy. objectives the aim of this study was to develop an artificial neural network (ann) model to predetermine individual responses to therapy based on patient’s dem...

BACKGROUND Chronic delta hepatitis virus (HDV) infection rapidly progresses to cirrhosis. Treatment with peginterferon for up to 2 years is often without durable response. AIM To examine the efficacy and safety of long-term peginterferon in achieving a durable response. METHODS Treatment was initiated with 180 μg/week of peginterferon alfa-2a with titration to a maximal tolerable dose, for ...

conclusions both add-on ldt and switching to peg-ifn-α2a were satisfactory and optimal treatments for chb patients with poor responses to adv. both rescue strategies resulted in significant reductions in serum viral load and alt levels, and were associated with high rate of serological outcomes in our hospital. patients and methods ninety-seven chb patients with hbv dna > 2 log10 copies/ml 48 w...

Chronic hepatitis B (CHB) continues to be an important public health problem worldwide, including in the United States. An algorithm for managing CHB was developed by a panel of United States hepatologists in 2004 and subsequently updated in 2006 and 2008. Since 2008, additional data on long-term safety and efficacy of licensed therapies have become available and have better defined therapeutic...

INTRODUCTION Response to hepatitis C treatment is known to differ by race; and, limited data suggests by ethnicity as well. A lower efficacy of HCV therapy in Latinos has been observed; whether higher doses may improve the response is unknown. MATERIAL AND METHODS This study used the available data from the patients enrolled in the PROGRESS study and stratified it by race and ethnicity. The p...

In The Lancet Infectious Diseases, Eric Lawitz and colleagues report results from their randomised phase 2 trial, in which they showed a more than 90% cure rate of hepatitis C in patients given a combination of pegylated interferon alfa-2a (peginterferon), ribavirin, and sofosbuvir, a novel nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase. Among the 60 or so drugs under devel...

The addition of the hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir to peginterferon alfa with ribavirin therapy has increased cure rates in HCV infection. Numerous other direct-acting antivirals (DAAs) are in advanced stages of development, including next-generation protease inhibitors, nonstructural protein (NS) 5A inhibitors, and nonnucleoside and nucleos(t)ide NS5B pol...